Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 2/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 4/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12735639 | 0.92 | RARB (0.46) | CYP17A1RARBRARARARGMGLL | |
| SCHEMBL10301947 | 0.89 | RARB (0.46) | CYP17A1RARBRARARARGMGLL | |
| SCHEMBL10301943 | 0.88 | CYP17A1 (0.52) | CYP17A1MGLLNAAA | |
| SCHEMBL10303004 | 0.88 | CYP17A1 (0.55) | CYP17A1MGLLNAAA | |
| SCHEMBL10302214 | 0.88 | CYP17A1 (0.45) | CYP17A1RARBRARARARGMGLL | |
| SCHEMBL10979395 | 0.88 | RARB (0.58) | CYP17A1RARBRARARARGMGLL | |
| SCHEMBL10986661 | 0.87 | RARB (0.60) | CYP17A1RARBRARARARGMGLL | |
| SCHEMBL10980040 | 0.87 | RARB (0.60) | CYP17A1RARBRARARARGMGLL | |
| SCHEMBL10981389 | 0.87 | RARB (0.60) | CYP17A1RARBRARARARGMGLL | |
| SCHEMBL10978885 | 0.87 | RARB (0.60) | CYP17A1RARBRARARARGMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | CYP17A1 1641/4885RARB 3213/4885RARA 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.